Exciting New Research Showing a Clear Role for Resveratrol in Oral Health

December 18th, 2018

Evolva is currently collaborating on two studies in the area of oral health:

  • A study led by Dr. Howard Tenenbaum (University of Toronto, Canada). 40 smokers with chronic periodontitis for 6 months. Veri-te™ resveratrol (500 mg) daily in combination with scaling and root planing. Focus on periodontitis via clinical and biological improvements with biochemical and structural parameters. The initial study is now finished with significant data showing a larger reduction in periodontal inflammation in patients taking Veri-te™ as compared to the control. Every patient on Veri-te™ showed reductions in inflammatory markers for periodontitis that were, in all cases, better than those seen for patients on placebo. However, the study is currently underpowered (more participants required), thus the researchers are recruiting further subjects and will continue the study before publishing.


  • A study led by Dr. Marcio Zaffalon Casati (U. Paulista, Sao Paulo, Brazil). 64 smokers for 6+6 months. Veri-te™ resveratrol (500 mg) daily. Focus on periodontitis via biochemical and structural parameters. Completion of the study is expected by late 2018.


An abstract is now available for a further study in the area of oral health showing that resveratrol reduces hallitosis.

Compounded Orodispersible Films with Natural Ingredients for Halitosis: A Clinical Experience.

Halitosis can be described as unpleasant odors emanating from the oral cavity. It is usually associated with decomposition action of bacteria present mainly on the back of the tongue and periodontal pockets, and able to produce volatile sulfur compounds. We conducted a study at the Faculty of Dentistry, Federal University of Juiz de Fora and evaluated the therapeutic effect of two natural extracts, Camellia sinensis (green tea) and resveratrol in the form of oral polymer films, to control halitosis. Fifty volunteers (students of health courses) participated in the research after orientation and signing the informed consent form. The anamnesis was made by researchers. The physical examination was made to verify the inclusion criteria. Each participant received 45 polymeric films to be consumed in 15 days (3 films per day). Measurements of the volatile sulfur compound levels were performed using a halimeter in two stages: 1) before use and 2) 15 days after the first administration. Results showed a statistically significant reduction in volatile sulfur compound levels in 71.79% of the volunteers. We concluded that the compounded orodispersible films containing green tea and resveratrol demonstrated excellent results in reducing halitosis.